Jiangsu Hengrui Medicine Co., Ltd. (SHA: 600276)

Market Cap	283.08B
Revenue (ttm)	26.00B
Net Income (ttm)	5.45B
Shares Out	6.36B
EPS (ttm)	0.86
PE Ratio	51.78
Forward PE	47.61
Dividend	0.20 (0.47%)
Ex-Dividend Date	Jul 12, 2024

Volume	40,490,394
Average Volume	28,841,098
Open	43.29
Previous Close	42.84
Day's Range	43.28 - 45.36
52-Week Range	35.51 - 57.53
Beta	0.27
RSI	45.60
Earnings Date	Mar 31, 2025

About Jiangsu Hengrui Medicine

Jiangsu Hengrui Medicine Co., Ltd., a pharmaceutical company, develops, manufactures, and commercializes drugs worldwide. The company is developing Camrelizumab, Pyrotinib, Fuzuloparib, Adebrelimab, Rezvilutamide, Famitinib, Dalpiciclib, SHR-1701, SHR-1501, SHR-A1811, SHR1459, Mecapegfilgrastim, Apatinib, Linperlisib, and SHR2554 for oncology indications; SHR4640, Retagliptin, SHR20004, SHR-1209, SHR3824, INS068, SHR7280, and SHR2285 for cardiovascular and metabolism indications. It is also developing SHR0302, Hetrombopag, Vunakizumab, and SHR-...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1970
• Employees: 19,611
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600276

Financial Performance

In 2023, Jiangsu Hengrui Medicine's revenue was 22.82 billion, an increase of 7.26% compared to the previous year's 21.28 billion. Earnings were 4.30 billion, an increase of 10.14%.